These symptoms are not always easy to spot and are commonly dismissed as signs of ageing, so all the more reason to be ...

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹ Recommendation based ...

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based o ...

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing ...

Among patients receiving ICIs, rh-irAEs are usually moderate or severe, with more than one-third leading to ICI discontinuation.

EMA committee recommends marketing approval for Novartis Cosentyx in polymyalgia rheumatica: Basel Monday, September 21, 2026, 14:00 Hrs [IST] Novartis announced that the Committe ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for ...

Morning stiffness often gets dismissed as part of ageing, but persistent symptoms may sometimes indicate an underlying ...

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica ...

ALCOR Scientific reports that labs' four-hour ESR test stability limit leads to inaccuracies due to sample handling.

Novartis AG ( NVS ), a pharmaceutical company, on Friday reported receiving a positive opinion from the Centre for Human use of Medicinal Products (CHMP) for Cosentyx in the treatment of polymyalgia ...

For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually ...